In parallel, supraphysiological pulses re-programme tumour-associated macrophages toward an iNOS-rich M1 phenotype, amplify granzyme-B output from CD8+ T cells and down-tune PD-L1 expression on malignant and myeloid cells, thereby widening the therapeutic window of immune-checkpoint blockade. The gene discussed is GZMB; the disease is neoplasm.